ACE and ovarian carcinoma: With a 5-year follow-up, antihypertensive drugs were not associated with survival from ovarian cancer but with 10-year follow-up, ACE-inhibitors and with longer follow-up times also other antihypertensive drugs were associated with improved survival from ovarian cancer.